Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

Background KN046 is a novel bispecific antibody targeting programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This multicenter phase I trial investigated the safety, tolerability, pharmacokinetics (PK), and efficacy of KN046 in patients with advanced solid tum...

Full description

Bibliographic Details
Main Authors: Yang Zhang, Yan Huang, Li Zhang, Jie Sun, Hongyun Zhao, Yunpeng Yang, Wenfeng Fang, Yuanyuan Zhao, Yuxiang Ma, Qun Li, Ye Guo, Yuhan Zhang, Jinhui Xue, Xiaoxiao Ge, Bangyong Zhang, Jinyuan Xiao
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/6/e006654.full

Internet

https://jitc.bmj.com/content/11/6/e006654.full

Similar Items